Department of Molecular and Microbiology, George Mason University, Manassas, VA 20110, United States.
Biochem Biophys Res Commun. 2010 May 28;396(2):246-51. doi: 10.1016/j.bbrc.2010.04.073. Epub 2010 Apr 23.
Francisella infects the lungs causing pneumonic tularemia. Focusing on the lung's host defense, we have examined antimicrobial peptides as part of the innate immune response to Francisella infection. Interest in antimicrobial peptides, such as the cathelicidins, has grown due their potential therapeutic applications and the increasing problem of bacterial resistance to commonly used antibiotics. Only one human cathelicidin, LL-37, has been characterized. Helical cathelicidins have also been discovered in snakes including the Chinese King Cobra, Naja atra (NA-CATH). Four synthetic 11-residue peptides (ATRA-1, -2, -1A and -1P) containing variations of a repeated motif within NA-CATH were designed. We hypothesized that these smaller synthetic peptides could have excellent antimicrobial effectiveness with shorter length (and less cost), making them strong potential candidates for development into broad-spectrum antimicrobial compounds. We tested the susceptibility of F. novicida to four ATRA peptides, LL-37, and NA-CATH. Two of the ATRA peptides had high antimicrobial activity (microM), while the two proline-containing ATRA peptides had low activity. The ATRA peptides did not show significant hemolytic activity even at high peptide concentration, indicating low cytotoxicity against host cells. NA-CATH killed Francisella bacteria more quickly than LL-37. However, LL-37 was the most effective peptide against F. novicida (EC50=50 nM). LL-37 mRNA was induced in A549 cells by Francisella infection. We recently demonstrated that F. novicida forms in vitro biofilms. LL-37 inhibited F. novicida biofilm formation at sub-antimicrobial concentrations. Understanding the properties of these peptides, and their endogenous expression in the lung could lead to potential future therapeutic interventions for this lung infection.
弗朗西斯菌感染肺部引起肺鼠疫。我们专注于肺部的宿主防御,研究了抗菌肽作为宿主对弗朗西斯菌感染的先天免疫反应的一部分。由于抗菌肽(如 cathelicidins)具有潜在的治疗应用以及细菌对常用抗生素的耐药性日益增加的问题,人们对其产生了兴趣。目前仅鉴定出一种人类 cathelicidin,即 LL-37。还在蛇中发现了螺旋状的 cathelicidins,包括中国眼镜蛇(Naja atra)(NA-CATH)。设计了四个包含 NA-CATH 内重复基序变体的 11 个残基合成肽(ATRA-1、-2、-1A 和-1P)。我们假设这些较小的合成肽可能具有出色的抗菌效果,同时长度较短(成本更低),因此它们是开发广谱抗菌化合物的潜在有力候选物。我们测试了 F. novicida 对四种 ATRA 肽、LL-37 和 NA-CATH 的敏感性。两种 ATRA 肽具有很高的抗菌活性(微摩尔),而两种脯氨酸含量较高的 ATRA 肽活性较低。即使在高肽浓度下,ATRA 肽也没有表现出明显的溶血活性,表明对宿主细胞的细胞毒性低。NA-CATH 比 LL-37 更快地杀死弗朗西斯菌。然而,LL-37 是对抗 F. novicida 最有效的肽(EC50=50 nM)。LL-37 可诱导 A549 细胞中弗朗西斯菌感染的 mRNA 表达。我们最近证明 F. novicida 可在体外形成生物膜。亚抗菌浓度的 LL-37 抑制 F. novicida 生物膜的形成。了解这些肽的特性及其在肺部的内源性表达,可能为这种肺部感染带来潜在的未来治疗干预。